Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

• Status: Completed
• Trial end date: 2007-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate the safety and efficacy of RSD1235 compared to placebo in the conversion of atrial arrhythmia to sinus rhythm in subjects following valvular and/or coronary artery bypass graft surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborators: Astellas Pharma US, Inc.; Cardiome Pharma; Correvio International Sarl

Criteria

Inclusion Criteria:

• Documented atrial arrhythmia after valvular and/or coronary artery bypass graft surgery

Exclusion Criteria:

• Unstable Class IV heart failure